McDermott Will & Schulte, a global law firm

Anthony Paronneau focuses his practice on a broad range of corporate and transactional matters, with a particular focus on the pharmaceutical, medical device, biotech, and healthcare sectors.

He has extensive experience representing life sciences companies, private equity funds, and venture capital firms in complex M&A and private equity transactions, including acquisitions, venture financings, joint ventures, and divestitures.

See More

• Advised a syndicate of Amolyt Pharma’s historical investors on its EUR130 million Series C financing.
• Advised TRiCares, a pioneer in the minimally invasive treatment of tricuspid regurgitation, on its €47 million financing round following the closing of its Series C financing round
• Advised Biocorp Production SA, a French company listed on Euronext Growth which specializes in the design, development and manufacturing of delivery systems and innovative medical devices, including Mallya, a Bluetooth enabled smart add-on device for pen injectors, on its proposed acquisition by Novo Nordisk A/S.
• Advised Sofinnova Partners on the EUR 15 million investment in Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, led by Sofinnova with participation from Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog
• Advised Crédit Mutuel Innovation on the Series C financing of UroMems, an international company developing an innovative, implantable mechatronic technology to treat stress urinary incontinence (SUI).

See More

• The Legal 500 EMEA, Leading Individual in France: Healthcare & Life Sciences, 2022-2026
• Chambers France, Band 2 in Pharma/Life Sciences: Corporate, 2026
• The Best Lawyers in France, Biotechnology & Life Sciences, 2025 & 2026
• Chambers Europe, France: Pharma/Life Sciences: Corporate, 2022-2024
• IFLR1000, Corporate and M&A, 2022-2023

See More